Jungla
Jungla Inc. was a Stanford-founded biotechnology company (2016-2019) that built the Molecular Evidence Platform, an active learning engine integrating functional genomics and computational biophysics to interpret clinical genetic variants for clinical laboratories, pharmaceutical companies, and healthtech firms.
- Company typePrivate
- Founded2016
- HeadquartersSouth San Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Jungla does
Jungla Inc. was a South San Francisco-based biotechnology company founded in 2016 by three Stanford PhDs (Carlos Araya, Alex Colavin, Jason Reuter) that developed the Molecular Evidence Platform (MEP), an active learning engine for clinical genetic variant interpretation. The MEP combined large-scale functional genomics (wet lab methods) with computational biophysics and integrative computational modeling (dry lab methods) to systematically generate, evaluate, audit, and distribute evidence models evaluating how genetic variants impact molecular, cellular, and evolutionary processes. The platform addressed the core problem that less than 1% of genetic variants in the human population are clinically understood, providing robust, quantitative, and transparent clinical guidance for molecular diagnostic and screening tests as well as therapeutic interventions. Disclosed performance metrics included >=95% prospective accuracy (exceeding ACMG/AMP recommendations), coverage of over 100,000 molecular variants at ~85% completeness, and support for hundreds of genes and conditions.
The company served three primary customer segments through a B2B enterprise partnership model: leading clinical laboratories seeking enhanced functional evidence for variant interpretation (primary segment), pharmaceutical companies requiring variant interpretation for drug development and personalized medicine, and IT firms building precision medicine infrastructure. Revenue was generated through subscription/recurring platform licensing and partnership services distributed via direct enterprise engagements, with inquiries managed through dedicated email channels rather than traditional sales motions. Jungla raised approximately $2.8M in total disclosed venture funding (a $250K seed from SOSV/IndieBio in March 2016 and a $2.55M Series A led by Andreessen Horowitz in November 2016) and maintained a lean team of 1-10 employees. In July 2019, Invitae Corporation acquired Jungla for approximately $65 million to extend its variant interpretation capabilities with supplemental RNA analysis, ending Jungla's independent operations.
Jungla firmographics
Firmographics- Name
- Jungla
- Legal name
- Jungla Inc.
- Website
- https://jungla.bio
- Company type
- Private
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Jungla Inc. was a Stanford-founded biotechnology company (2016-2019) that built the Molecular Evidence Platform, an active learning engine integrating functional genomics and computational biophysics to interpret clinical genetic variants for clinical laboratories, pharmaceutical companies, and healthtech firms.
- Ownership category
- akta.pro rank
Jungla industry classification
Industry- Product category
- Clinical Genomics Software
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Jungla is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Jungla business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Platform Licensing and Partnership Services: B2B revenue model through partnerships with clinical laboratories, pharmaceutical companies, and IT firms. The company provides its Molecular Evidence Platform as infrastructure to enhance precision medicine capabilities of partners.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Jungla product offering
Product offeringCore offering
Jungla developed and sold the Molecular Evidence Platform (MEP), an active learning engine that integrates functional genomics and computational biophysics to systematically generate, evaluate, audit, and distribute evidence models for clinical genetic variant interpretation. The platform enabled clinical laboratories, pharmaceutical companies, and IT firms to deliver robust, quantitative, and transparent clinical guidance for molecular diagnostic tests, screening tests, and therapeutic interventions, addressing the gap that less than 1% of genetic variants are clinically understood.
Product overview
Jungla offers a single unified product—the Molecular Evidence Platform (MEP)—which provides variant interpretation solutions for clinical genetic and genomic testing. The MEP is an active learning engine that continuously integrates and enhances clinical knowledge with functional and computational evidence, systematically generating, evaluating, and auditing evidence models. The platform delivers robust, quantitative, and transparent clinical guidance with demonstrated prospective accuracy exceeding 95%, covering over 100,000 molecular variants across hundreds of genes and conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Molecular Evidence Platform (MEP)
- Variant Interpretation Solutions Solutions that augment and optimize guidance in clinical genetic and genomic tests, enabling clinicians to look deeper into genomes to overcome uncertainty in clinical interpretation where less than 1% of genetic variants are clinically understood. Delivered to clinical laboratories and partners as part of the Molecular Evidence Platform offering.
Quantifiable outcome
- >=95% Prospective Accuracy exceeds ACMG/AMP recommendations
- +3 more outcomes
Companies that use Jungla
Customer profileSegments3 records
Ideal customer profiles3 records
Jungla technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Jungla partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Invitae CorporationcoreInvitae Corporation announced acquisition of Jungla Inc. in July 2019. This acquisition was intended to advance genetic variant interpretation and add supplemental RNA analysis capabilities to deliver deeper, more informative results to patients.
- Hewlett Packard EnterprisecoreHPE partnered with Jungla through Tech Impact 2030 initiative to advance precision medicine using memory-driven computing. The partnership demonstrated memory-driven improvements in high-resolution molecular analyses, achieving >200x faster compute time (0.4% of original compute time). Jungla was featured in 'Reimagining Medical Testing' and 'The Future of AI' platform sessions at HPE Discover 2018.
- JLABS / Johnson & Johnson InnovationminorJungla was selected for participation as one of JLABS HealthTech startups at the NYC program in November 2018, gaining access to Johnson & Johnson Innovation ecosystem.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Jungla competitors and assessment
Company assessmentDirect peers
- Fabric Genomics: Fabric Genomics builds AI-driven clinical genomics interpretation platforms for rare disease and oncology diagnostics. It is the most direct peer to Jungla, operating a software platform that ingests sequencing data and produces ranked, clinically-actionable variant calls for hospital and lab customers.
- Sophia Genetics: Sophia Genetics combines AI with multimodal clinical and genomic data to support diagnosis and treatment decisions across hospital systems. It directly overlaps Jungla's positioning as an AI platform that translates complex genomic inputs into standardized, clinically-actionable outputs for healthcare providers.
Others
- DNAnexus: DNAnexus operates a cloud-based genomics data platform used by clinical labs and pharma for sequencing data management and analysis pipelines. It is an enabling/infrastructure peer that complements rather than directly competes with Jungla's interpretation layer.
Broad incumbents
- Illumina: Illumina is the dominant sequencing platform provider and increasingly offers downstream interpretation and clinical informatics solutions (e.g., Illumina Connected Analytics, TruSight). It is a broad incumbent that influences the variant interpretation ecosystem Jungla operates in.
- Color Genomics: Color provides population-scale genetic testing across hereditary cancer, cardiovascular, and pharmacogenomics. While more consumer-facing than Jungla, it relies on the same variant interpretation pipelines and competes for clinical variant interpretation partnerships.
- GeneDx: GeneDx is a major clinical genomics lab providing rare disease, hereditary cancer, and whole-exome interpretation at scale. It is a broad incumbent customer/prospect for variant interpretation technology comparable to Jungla's Molecular Evidence Platform.
- Ambry Genetics: Ambry Genetics is a clinical genetic testing laboratory with deep expertise in hereditary cancer and rare disease variant interpretation. It represents a potential enterprise customer profile similar to Jungla's clinical laboratory segment.
- Invitae Corporation: Invitae is a large clinical genetics testing company that acquired Jungla in 2019. Beyond the acquisition relationship, Invitae is a broad incumbent serving clinical variant interpretation needs at scale, overlapping with Jungla's core use case of providing variant interpretation to clinical labs and providers.
Emerging players
- Deep Genomics: Deep Genomics applies machine learning to identify novel genetic targets and predict variant effects on RNA biology. It overlaps Jungla's core competency in computational prediction of variant functional impact, although Deep Genomics is more therapeutics-development oriented.
Regional players
- BC Platforms: BC Platforms provides genomic data management and analytics platforms primarily in Europe, with comparable offerings to Jungla in clinical variant interpretation. It is a regional peer with similar underlying technology approach but different geographic focus.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Jungla social profiles
Digital presenceJungla financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jungla leadership team
Management profileNumber of profiles
Profiles8 records
Jungla funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jungla M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jungla
What does Jungla do?
Jungla developed and sold the Molecular Evidence Platform (MEP), an active learning engine that integrates functional genomics and computational biophysics to systematically generate, evaluate, audit, and distribute evidence models for clinical genetic variant interpretation. The platform enabled clinical laboratories, pharmaceutical companies, and IT firms to deliver robust, quantitative, and transparent clinical guidance for molecular diagnostic tests, screening tests, and therapeutic interventions, addressing the gap that less than 1% of genetic variants are clinically understood.
Is Jungla a public or private company?
Jungla is a private company. It is classified as corporate owned and is currently acquired.
When was Jungla founded?
Jungla was founded in 2016. It employs 1 to 10 people.
Where is Jungla based?
Jungla is headquartered in South San Francisco, United States, in the North America region.
How does Jungla make money?
One revenue line is on record: platform Licensing and Partnership Services.
Who are Jungla's main competitors?
Direct peers on record are Fabric Genomics and Sophia Genetics. DNAnexus is listed as an others. Broad incumbents are Illumina, Color Genomics, GeneDx, Ambry Genetics and Invitae Corporation. Deep Genomics is listed as an emerging player. BC Platforms is listed as a regional player.
Does Jungla have an API?
No public API is recorded for Jungla.
What industry is Jungla in?
Jungla's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 621511 and its SIC code is 8071.